目的 探讨疏风解毒胶囊治疗新型冠状病毒肺炎（COVID-19）的分子机制。方法 借助中药系统药理学分析平台（TCMSP）检索疏风解毒胶囊有效活性成分及作用靶点。运用GeneGards等数据库对疾病靶点进行筛选，使用Cytoscape 3.7.2软件构建活性成分-靶点网络和蛋白互作（PPI）网络，通过DAVID数据库对靶点进行GO功能分析和KEGG通路富集分析。结果 共得到疏风解毒胶囊有效活性成分共207个，其中作用于COVID-19的60个活性成分可通过46个潜在靶标作用于COVID-19。富集得到GO中1 343个生物过程条目和6条KEGG通路，涉及内分泌抵抗、MAPK信号通路、精氨酸生物合成路径等。结论 疏风解毒胶囊主要通过黄酮类和植物甾醇类活性成分调节IL6、IL1B、CCL2、MAPK8、MAPK1、MAPK14、CASP3、FOS、ALB等关键靶点，调控炎症反应、氧化应激损伤、细胞凋亡、肺纤维化增生等过程减轻肺损伤来治疗COVID-19。

Objective To explore the molecular mechanism of Shufeng Jiedu Capsule in the treatment of corona virus disease (COVID-19). Methods The active composition and action targets of Shufeng Jiedu Capsule were searched with TCMSP. The GeneGards database was used to screen out the targets of related to COVID-19. The active ingredient-target network and PPI protein interaction network were established using Cytoscape 3.7.2 software. GO functional analysis and KEGG pathway enrichment analysis of targets were performed using DAVID database. Results A total of 207 effective active ingredients of Shufeng Jiedu Capsule were obtained, which can act on COVID-19 through 46 potential targets. GO functional enrichment analysis obtained 1 343 GO items, KEGG pathway enrichment analysis obtained six pathways, involving endocrine resistance, MAPK signaling pathway, arginine biosynthesis pathway, etc. Conclusion Shufeng Jiedu Capsule regulates key targets such as IL6, IL1B, CCL2, MAPK8, MAPK1, MAPK14, CASP3, FOS, and ALB mainly through flavonoids and phytosterol active ingredients by regulating inflammatory response, oxidative stress injury, apoptosis, pulmonary fibrosis, and other processes to reduce lung injury and then treating COVID-19.

R285.5

上海市临床重点专科项目（shslczdzk05401）；中医糖尿病专科联盟建设项目[ZY（2018-2020）-FWTX-4011]；上海市科委科研计划项目（17401970100）；上海市中医临床重点实验室项目（14DZ2273200）；上海市临床重点专科项目（shslczdzk05101）；上海中医药大学防治新型冠状病毒（2019.nCoV）应急科研攻关项目（2020YJ01）